Master Class

Overcoming Challenges in the Treatment of MDD: Non-Monoaminergic Therapies and Precision Psychiatry Considerations

Speaker(s)

• 

  Craig Chepke, MD, DFAPA

  Medical Director, Excel Psychiatric Associates; Adjunct Associate Professor of Psychiatry, Atrium Health
  Excel Psychiatric Associates
• 

  Rakesh Jain, MD

  Clinical Professor
  Texas Tech - Permian Basin
  Texas Tech University School of Medicine - Permian Basin, Midland, Texas
• CM

  Cheryl Meier

  Patient Advocate
  Midwest Research Group

Up to one-third of individuals experiencing MDD symptoms do not respond to treatment, and traditional antidepressants require weeks of administration before therapeutic effects are observed. This session is designed to empower psychiatric clinicians with the latest insights and practical skills for optimizing MDD treatment strategies. Throughout this session, expert faculty will delve into the assessment of current challenges inherent in the MDD treatment landscape, highlighting the necessity for innovative treatment approaches. Participants will gain a deep understanding of the current understanding of MDD pathophysiology and its intricate impact on various neurobiological systems. Attendees will then be equipped to evaluate the most recent safety and efficacy data associated with both current and emerging novel treatment options in MDD. This knowledge will enable participants to seamlessly incorporate novel treatment options into their clinical practice, aligning with the evolving MDD treatment paradigm.

Supported by an educational grant from Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC.